| Name | Title | Contact Details |
|---|
Idenix Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Idenix Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on Idenix Pharmaceuticals, Inc. at www.idenix.com
Capitol Drugs is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sherman Oaks, CA. To find more information about Capitol Drugs, please visit www.capitoldrugs.com
Gallipot, Inc is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1968 our goal has been straightforward: help patients get their life back on track and achieve a life of sobriety, free from drug use and symptoms of mental illness. A life that is productive, socially responsible and healthy. Gateway Foundation is one of the nation`s largest nonprofit provider of substance use disorder treatment and a nationally recognized leader in the field of addiction medicine. With treatment programs in Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas and Wyoming we specialize in substance use disorders for patients diagnosed with substance use disorder and mental health disorders. Gateway Foundation`s professional clinicians support over 9,000 people a day to successfully complete treatment by developing a personalized plan to treat the underlying causes of substance use disorder—not just their addiction to drugs or alcohol.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.